Literature DB >> 11855984

Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins.

Simon L Goodman1, Günter Hölzemann, Gábor A G Sulyok, Horst Kessler.   

Abstract

Integrin adhesion receptors frequently recognize a core amino acid sequence, Arg-Gly-Asp, in their target ligands. Inhibitors with the ability to inhibit one or a small subset of such RGD-dependent integrins have been invaluable in defining their biological function. Here, we have characterized low molecular weight inhibitors for their ability to specifically inhibit alphav(beta)6 integrin, a fibronectin/tenascin receptor. As of yet, no nonpeptidic inhibitor of alphav(beta)6 was known. New peptidomimetic and nonpeptidic compounds were examined in isolated integrin binding assays and in cell adhesion assays for their ability to block alphav(beta)6, alphav(beta)3, alphav(beta)5, and alphalIb(beta)3 integrins. The compounds are based on an aromatically substituted beta amino acid or glutaric acid derivative as an acidic center and an aminopyridyl or guanidyl residue as a basic mimetic. We found several classes of inhibitors with different selectivities, especially mono- or biselectivity on the alpha(v)-integrins alphav(beta)6 and alphav(beta)3, and nanomolar activity. Furthermore, nearly all compounds are inactive on alphaIIb(beta)3. Compound 11 is the first specific, peptidomimetic inhibitor of the alphav(beta)6 integrin receptor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11855984     DOI: 10.1021/jm0102598

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  50 in total

1.  Discovery and Characterization of a Potent and Specific Peptide Ligand Targeting Endothelial Progenitor Cells and Endothelial Cells for Tissue Regeneration.

Authors:  Dake Hao; Wenwu Xiao; Ruiwu Liu; Priyadarsini Kumar; Yuanpei Li; Ping Zhou; Fuzheng Guo; Diana L Farmer; Kit S Lam; Fengshan Wang; Aijun Wang
Journal:  ACS Chem Biol       Date:  2017-03-02       Impact factor: 5.100

Review 2.  Integrin-mediated transforming growth factor-beta activation, a potential therapeutic target in fibrogenic disorders.

Authors:  Stephen L Nishimura
Journal:  Am J Pathol       Date:  2009-09-03       Impact factor: 4.307

3.  Development of a chimeric recombinant disintegrin as a cost-effective anti-cancer agent with promising translational potential.

Authors:  Radu Minea; Corey Helchowski; Barbara Rubino; Kyle Brodmann; Stephen Swenson; Francis Markland
Journal:  Toxicon       Date:  2011-02-24       Impact factor: 3.033

4.  Structure Activity Relationships of αv Integrin Antagonists for Pulmonary Fibrosis by Variation in Aryl Substituents.

Authors:  James Adams; Edward C Anderson; Emma E Blackham; Yin Wa Ryan Chiu; Thomas Clarke; Natasha Eccles; Luke A Gill; Joshua J Haye; Harvey T Haywood; Christian R Hoenig; Marius Kausas; Joelle Le; Hannah L Russell; Christopher Smedley; William J Tipping; Tom Tongue; Charlotte C Wood; Jason Yeung; James E Rowedder; M Jonathan Fray; Thomas McInally; Simon J F Macdonald
Journal:  ACS Med Chem Lett       Date:  2014-09-19       Impact factor: 4.345

5.  Relative binding affinities of integrin antagonists by equilibrium dialysis and liquid chromatography-mass spectrometry.

Authors:  William J Tipping; Nkazimulo Tshuma; James Adams; Harvey T Haywood; James E Rowedder; M Jonathan Fray; Thomas McInally; Simon J F Macdonald; Neil J Oldham
Journal:  ACS Med Chem Lett       Date:  2014-12-22       Impact factor: 4.345

6.  Small-molecule-modified surfaces engage cells through the αvβ3 integrin.

Authors:  Joseph R Klim; Anthony J Fowler; Adam H Courtney; Paul J Wrighton; Rachael T C Sheridan; Margaret L Wong; Laura L Kiessling
Journal:  ACS Chem Biol       Date:  2012-01-26       Impact factor: 5.100

Review 7.  Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner.

Authors:  Thomas Dittmar; Christoph Heyder; Eva Gloria-Maercker; Wolfgang Hatzmann; Kurt S Zänker
Journal:  Clin Exp Metastasis       Date:  2007-09-08       Impact factor: 5.150

8.  Vicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities.

Authors:  Radu O Minea; Corey M Helchowski; Samuel J Zidovetzki; Fritz K Costa; Stephen D Swenson; Francis S Markland
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

9.  Selective Detection of RGD-Integrin Binding in Cancer Cells Using Tip Enhanced Raman Scattering Microscopy.

Authors:  Lifu Xiao; Hao Wang; Zachary D Schultz
Journal:  Anal Chem       Date:  2016-05-27       Impact factor: 6.986

10.  Rapid endothelialization of small diameter vascular grafts by a bioactive integrin-binding ligand specifically targeting endothelial progenitor cells and endothelial cells.

Authors:  Dake Hao; Yahan Fan; Wenwu Xiao; Ruiwu Liu; Christopher Pivetti; Tanaya Walimbe; Fuzheng Guo; Xinke Zhang; Diana L Farmer; Fengshan Wang; Alyssa Panitch; Kit S Lam; Aijun Wang
Journal:  Acta Biomater       Date:  2020-03-07       Impact factor: 8.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.